<div id="readability-page-1"><article><div id="ps-bar">See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens GoogleAdd on Google</div>Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference. The Company will provide an overview and update of its innovative current late-stage portfolio. Key highlights include: Privosegtor, a novel neuroprotective candidate which received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for optic neuritis (ON), in the PIONEER registrational program to address unmet needs for two optic neuropathies and to unlock a potential market opportunity of $7B+ in the U.S. alone, and Licaminlimab, a topical anti-TNFα being evaluated in the PREDICT-1 registrational trial as the first genotype-based precision medicine in dry eye disease (DED). With a strong balance sheet and advanced pipeline, Oculis prepares to deliver several pivotal readouts with the current funding, focusing on fulfilling its mission to save sight and improve eye care with groundbreaking treatments. 47th Annual Goldman Sachs Global Healthcare Conference Date: June 9, 4:00pm ET Location: Miami, FL Format: Fireside chat Presenter: Dr. Riad Sherif, CEO Webcast link: Register here The Company will be available for one-on-one meetings during the conference. Interested investors should contact their respective representative at the sponsoring institutions to request meetings. Webcast links, when available, are posted to the Oculis website on the Events &amp; Presentations page under the Investors &amp; Media section. -ENDS- About Oculis Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neurological diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors. For more information, please visit: www.oculis.com Oculis Contacts Sylvia Cheung, CFO sylvia.cheung@oculis.com Investor Relations LifeSci Advisors Corey Davis, Ph.D. cdavis@lifesciadvisors.com Media Relations ICR Healthcare Amber Fennell / David Daley / Sean Leous oculis@icrhealthcare.com Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the initiation, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; expected milestones; statements about market opportunity; and statements about cash runway and capital needs, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the SEC. Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9TVRBd01URTROalU0TXlNME1ESTBNRFUzTWpZak1qRTRPVEF5TXc9PQ"/> <img src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml-eu.globenewswire.com/media/ZDgzMzk3ZTUtMGYyYy00ZGZkLTgxZWQtYWI5M2VkNTg2YWU4LTEyMDA1NzYtMjAyNi0wNi0wOC1lbg==/tiny/Oculis-Holding-AG.png"/></article></div>

Oculis Holding AG (Nasdaq: OCS) announced that its management, led by CEO Dr. Riad Sherif, will participate in a fireside chat at the 47th Annual Goldman Sachs Global Healthcare Conference on June 9 in Miami. The company will provide an overview of its late-stage portfolio, highlighting Privosegtor for optic neuritis and Licaminlimab for dry eye disease.

StockTitan

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference | OCS Stock News